Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GNS-20I04
- Development stage
- Unknown
- Lead developer
- Genewon Science
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GNS-20I04 is an improved small molecule drug developed by GenuOne Sciences for the treatment of type 2 diabetes. It is a fixed-dose combination (FDC) of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Classified as an 'improved drug' (개량신약) under South Korean regulatory standards, GNS-20I04 is designed to enhance glycemic control by utilizing two complementary mechanisms: dapagliflozin reduces blood glucose by inhibiting renal glucose reabsorption, while sitagliptin increases insulin secretion and suppresses glucagon release. GenuOne Sciences, a prominent South Korean CDMO, successfully progressed GNS-20I04 through Phase 3 clinical development to regulatory approval, subsequently marketing the product under the brand name Exfolia.
- Brand names
- Exfolia
- Other names
- Sitagliptin + Dapagliflozin
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on GNS-20I04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GNS-20I04.